You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

12 Items
Cancer Type: Hematologic, Leukemia - Acute Promyelocytic (APL)     
Intent: Palliative
Drugs Used:
arsenic trioxide (Unfunded)
May 2019
Cancer Type: Hematologic, Leukemia - Acute Promyelocytic (APL)     
Intent: Curative
Funding:
Exceptional Access Program
    tretinoin (ATRA)
New Drug Funding Program
    Arsenic Trioxide - First Line Consolidation of Acute Promyelocytic Leukemia (APL)
New Drug Funding Program
    Arsenic Trioxide - Relapsed_Refractory Consolidation of Acute Promyelocytic Leukemia (APL)
May 2019
Cancer Type: Hematologic, Leukemia - Acute Promyelocytic (APL)     
Intent: Curative
Funding:
New Drug Funding Program
    Arsenic Trioxide - First Line Consolidation of Acute Promyelocytic Leukemia (APL)
New Drug Funding Program
    Arsenic Trioxide - Relapsed_Refractory Consolidation of Acute Promyelocytic Leukemia (APL)
Exceptional Access Program
    tretinoin (ATRA)
May 2019
Cancer Type: Hematologic, Leukemia - Acute Promyelocytic (APL)     
Intent: Curative
Funding:
New Drug Funding Program
    Arsenic Trioxide - First Line Induction of Acute Promyelocytic Leukemia (APL)
New Drug Funding Program
    Arsenic Trioxide - Relapsed_Refractory Induction of Acute Promyelocytic Leukemia (APL)
Exceptional Access Program
    tretinoin (ATRA)
May 2019
Cancer Type: Hematologic, Leukemia - Acute Myeloid (AML)     
Intent: Palliative
Drugs Used:
enasidenib (Unfunded)
May 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
Exceptional Access Program
    everolimus - In combination with exemestane, for the treatment of hormone-receptor positive, HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)
ODB Limited Use
    exemestane - In combination with everolimus, for the treatment of hormone-receptor positive HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)
Jun 2019
Cancer Type: Breast     
Intent: Adjuvant
Funding:
ODB Limited Use
    exemestane - Sequential treatment of postmenopausal women with estrogen receptor-positive early breast cancer who have received 2-3 years of initial adjuvant tamoxifen therapy
Jun 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
ODB Limited Use
    exemestane - Hormonal treatment of metastatic breast cancer in hormone receptor positive postmenopausal women who have disease progression following tamoxifen therapy
Jun 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
Exceptional Access Program
    For the treatment of post-menopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative unresectable locally advanced breast cancer or metastatic breast cancer, according to clinical criteria
Drugs Used:
exemestane (Unfunded),
May 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
Exceptional Access Program
    For the treatment of breast cancer according to clinical criteria
Drugs Used:
exemestane (Unfunded),
Sep 2019
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia, according to specific clinical criteria
Jun 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), according to specific clinical criteria
Jun 2019